8-硝基二苯并[b,d]噻吩-3-磺酰氯 | 1025718-98-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 8-硝基二苯并[b,d]噻吩-3-磺酰氯
• 英文名称: 8-nitrodibenzo[b,d]thiophene-3-sulfonyl chloride
• 英文别名: 8-Nitrodibenzothiophene-3-sulfonyl chloride
• CAS: 1025718-98-2
• 化学式: C₁₂H₆ClNO₄S₂
• 分子量: 327.769
• InChiKey: IAMGJESYTIHDGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  117
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-硝基二苯并[b,d]噻吩-3-磺酰氯 、 D-缬氨酸叔丁基盐酸盐 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以72%的产率得到(R)-tert-butyl 3-methyl-2-(8-nitrodibenzo[b,d]thiophene-3-sulfonamido)butanoate
  参考文献：
  名称：

  Identification of an Orally Efficacious Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Asthma

  摘要：

  MMP-12 plays a significant role in airway inflammation and remodeling. Increased expression and production of MMP-12 have been observed in the lungs of asthmatic patients. Compound 27 was identified as a potent and selective MMP-12 inhibitor possessing good physicochemical properties. In pharmacological studies, the compound was orally efficacious in an MMP-12 induced ear-swelling inflammation model in the mouse with a good dose response. This compound also exhibited oral efficacy in a naturally Ascaris-sensitized sheep asthma model showing significant inhibition of the late phase response to allergen challenge. This compound has been considered for further development as a treatment therapy for asthma.

  DOI：

  10.1021/jm900809r
• 作为产物：
  描述：

  二苯并[b,d]噻吩-3-磺酰氯 在 硝酸 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 8-硝基二苯并[b,d]噻吩-3-磺酰氯
  参考文献：
  名称：

  WO2008/57254

  摘要：

  公开号：

文献信息

• WO2008/57254
  申请人：——

  公开号：——

  公开（公告）日：——
• TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Wyeth

  公开号：EP2074107A2

  公开（公告）日：2009-07-01
• [EN] TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES SERVANT D'INHIBITEURS DES MÉTALLOPROTÉASES MATRICIELLES
  申请人：WYETH CORP

  公开号：WO2008057254A2

  公开（公告）日：2008-05-15

  [EN] The present invention relates to compositions of the formula (I): and pharmaceutically acceptable salts, hydrates, or esters thereof, wherein R¹, R², R³, R⁴, R⁵, X, and Y are as defined herein. The present teachings also provide methods of making the compounds of formula I, and methods of treating pathologic conditions or disorders mediated wholly or in part by matrix metalloproteinases, such as asthma and chronic obstructive pulmonary disease, comprising administering a therapeutically effective amount of a compound of formula (I) to a mammal (e.g., a human) in need thereof.
  [FR] La présente invention concerne des composés de formule (I) : et des sels, hydrates ou esters acceptables du point de vue pharmaceutique de ceux-ci, R¹, R², R³, R⁴, R⁵, X et Y étant tels que définis ici. La présente invention concerne également des procédés de fabrication des composés de formule (I) et des procédés de traitement d'affections ou troubles pathologiques induits entièrement ou en partie par des métalloprotéases matricielles, tels que l'asthme et une bronchopneumopathie chronique obstructive, lesquels consistent à administrer une quantité efficace du point de vue thérapeutique d'un composé de formule (I) à un mammifère (par exemple à un humain) qui en a besoin.
• Identification of an Orally Efficacious Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Asthma
  作者：Wei Li、Jianchang Li、Yuchuan Wu、Fabio Rancati、Stefania Vallese、Luca Raveglia、Junjun Wu、Rajeev Hotchandani、Nathan Fuller、Kristina Cunningham、Paul Morgan、Susan Fish、Rustem Krykbaev、Xin Xu、Steve Tam、Samuel J. Goldman、William Abraham、Cara Williams、Joseph Sypek、Tarek S. Mansour

  DOI：10.1021/jm900809r

  日期：2009.9.10

  MMP-12 plays a significant role in airway inflammation and remodeling. Increased expression and production of MMP-12 have been observed in the lungs of asthmatic patients. Compound 27 was identified as a potent and selective MMP-12 inhibitor possessing good physicochemical properties. In pharmacological studies, the compound was orally efficacious in an MMP-12 induced ear-swelling inflammation model in the mouse with a good dose response. This compound also exhibited oral efficacy in a naturally Ascaris-sensitized sheep asthma model showing significant inhibition of the late phase response to allergen challenge. This compound has been considered for further development as a treatment therapy for asthma.